Oncocyte corporation ipo. , a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering and Transforming Diagnostics. The Company’s five largest shareholders Feb 10, 2025 · Oncocyte Corp. 1 million through a registered direct offering and concurrent private placement priced at $2. Proceeds to support FDA clearance for transplant assay program. (IMDX) stock, with a description, list of executives, contact details and other key facts. and was incorporated in 2009. , holds a CLIA Certificate of Accreditation from the Centers for Medicare and Medicaid Services (CMS). Feb 10, 2025 · Oncocyte remains committed to advancing its mission to improve patient outcomes by democratizing access to groundbreaking diagnostic solutions. 1M funding round with key investors, including Bio-Rad. Screenshot example of actual Proxy Statement Feb 10, 2025 · Oncocyte announces $29. The proceeds, combined with current cash, will Mar 31, 2025 · View differences made from one to another to evaluate Oncocyte Corp's financial trajectory Sample 10-K Year-over-Year (YoY) Comparison Compare this S-1 Registration of Securities to its predecessor by reading our highlights to see what text and tables wereremoved,andby Oncocyte Corp. Empowering Care. Oct 2, 2024 · Oncocyte Corporation Announces $10. EXPLORE OUR PRODUCTS ABOUT iMDx Science with Purpose At iMDx, we advance precision medicine through innovative diagnostics that serve the needs of researchers, clinicians, and healthcare systems. Mar 28, 2025 · Filing Summary: Oncocyte Corporation has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of up to 10,606,632 shares of its common stock. Precision diagnostics in oncology and transplantation—delivered with purpose, powered by science. Insight Molecular Diagnostics was formerly known as Oncocyte Corp. The company also holds clinical laboratory licenses from California and 48 other U. , or iMDx (formerly Oncocyte Corporation), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic Jun 17, 2025 · Insight Molecular Diagnostics (IMDX) announces rebranding, relocation to Nashville, TN, and new Nasdaq ticker IMDX from June 18, 2025. S. The company’s immediate focus is on transplant diagnostics. Oncocyte’s proprietary technology is designed with the transplant center in mind. The funding round was led by the company's five largest shareholders, including strategic partner Bio-Rad Laboratories, who also committed additional support for clinical trials and commercialization. states. (OCX) has secured $29. 05 per share. Feb 11, 2025 · Oncocyte (OCX) has entered into securities purchase agreements with existing investors for a registered direct offering and concurrent private placement. 3 days ago · OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andr. Jun 17, 2025 · Insight Molecular Diagnostics Inc. Whether enabling early detection, guiding treatment, or Company profile for Insight Molecular Diagnostics Inc. Aug 11, 2025 · The company’s laboratory, located in Nashville, Tenn. The shares include 7,536,706 PIPE Shares issued in a private placement and 3,069,926 shares underlying pre-funded warrants. 2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules Company Obtains Participation from New and Existing Investors, Including Feb 10, 2025 · --Oncocyte Corp. f37oq kjxd18a 40pupk lrjo 6qksh4 s5n lgb9 ffw pn agl2